Regentis Biomaterials

Company Overview

Snapshot

Founded in September 2004 by Prof. Dror Seliktar, Regentis Biomaterials operates with 1–10 employees. The company has raised a total of $43.5 million across 4 funding rounds from 8 investors. In September 2025, Regentis Biomaterials became publicly listed on NASDAQ.

Business overview

Regentis Biomaterials is a tissue-repair company specializing in developing and commercializing a hydrogel platform for regenerating damaged tissue. Their core product, GelrinC, is a cell-free, off-the-shelf hydrogel implant designed for orthopedic treatments, specifically for painful injuries to articular knee cartilage. The hydrogel acts as a scaffold, gradually eroding as new cartilage forms, and is completely resorbed within 6 to 12 months. The company operates within the Health Tech & Life Sciences sector, focusing on medical devices, medical treatment, therapeutics, biomaterials, and tissue engineering.

Strategic signal

Regentis Biomaterials is accelerating its commercial launch preparations for GelrinC in Europe, with plans to commence surgeon training in June 2026. This move, alongside receiving European regulatory approval for a new manufacturing process that increases GelrinC production yield by 400% in July 2026, signals a significant push towards market expansion and readiness for broader commercialization. These developments indicate strong operational progress and strategic positioning to capture a larger share of the cartilage repair market.

Company Intelligence Q&A

When did Regentis Biomaterials become a public company?

Regentis Biomaterials became publicly listed on NASDAQ in September 2025.

What was a significant recent development regarding GelrinC's manufacturing process?

In July 2026, Regentis Biomaterials received European regulatory approval for a new GelrinC manufacturing process, which increases production yield by 400%.

What is Regentis Biomaterials' primary product?

Regentis Biomaterials' primary product is GelrinC, a cell-free, off-the-shelf hydrogel implant for treating articular knee cartilage injuries.

Has Regentis Biomaterials expanded its intellectual property portfolio recently?

In July 2026, Regentis received Japanese patent allowance, strengthening its global GelrinC intellectual property portfolio with new proprietary manufacturing technology.

What is Regentis Biomaterials' strategy for European market entry?

Regentis Biomaterials is commencing European surgeon training for GelrinC in June 2026 as part of its accelerated commercial launch preparations.